Copyright: ©Author(s) 2026.
World J Gastrointest Oncol. Nov 15, 2026; 18(11): 123432
Published online Nov 15, 2026. doi: 10.4251/wjgo.123432
Published online Nov 15, 2026. doi: 10.4251/wjgo.123432
Table 1 Baseline characteristics of discordant and concordant groups, n (%) or median (interquartile range)
| Characteristic | Discordant (n = 172) | Concordant (n = 207) | P value |
| Age | 61 (55-67) | 61 (56-66) | 0.78 |
| Male sex | 63 (36.6) | 100 (48.3) | 0.03 |
| Race/ethnicity | |||
| Hispanic | 129 (75.0) | 147 (71.0) | 0.42 |
| White non-Hispanic | 4 (2.3) | 15 (7.2) | 0.03 |
| Asian | 9 (5.2) | 11 (5.3) | 1.00 |
| Black | 12 (7.0) | 9 (4.3) | 0.37 |
| Other/unknown | 18 (10.5) | 25 (12.1) | 0.75 |
| Foregut symptoms | 76 (44.2) | 79 (38.2) | 0.25 |
| Anemia at FIT | 60 (34.9) | 77 (37.2) | 0.67 |
| Hemoglobin (g/L) | 128 (112-140) | 131 (114-145) | 0.18 |
| MCV | 88.6 (83.3-91.0) | 89.3 (83.8-93.1) | 0.10 |
| Cirrhosis | 18 (10.5) | 58 (28.0) | < 0.001 |
| NSAID/aspirin use | 61 (35.5) | 57 (27.5) | 0.12 |
| Smoking status | |||
| Never | 145 (84.3) | 164 (79.2) | |
| Former | 21 (12.2) | 28 (13.5) | |
| Current | 6 (3.5) | 15 (7.2) | |
| Ever-smoker | 27 (15.7) | 43 (20.8) | 0.23 |
| Alcohol use | |||
| None | 121 (70.3) | 118 (57.0) | |
| Low-risk drinking | 22 (12.8) | 18 (8.7) | |
| Heavy drinking/AUD | 9 (5.2) | 35 (16.9) | < 0.001 |
| Any alcohol use | 31 (18.0) | 53 (25.6) | 0.08 |
| Not documented | 20 (11.6) | 36 (17.4) | |
| Insurance type | 0.045 | ||
| Medi-Cal | 112 (65.1) | 111 (53.6) | |
| Medicare | 18 (10.5) | 20 (9.7) | |
| Uninsured | 10 (5.8) | 12 (5.8) | |
| Private | 2 (1.2) | 0 (0.0) | |
| Other | 10 (5.8) | 28 (13.5) | |
| Not documented | 20 (11.6) | 36 (17.4) | |
| Gastric biopsy obtained | 162 (94.2) | 193 (93.2) | 0.83 |
| Same-day bidirectional | 79 (45.9) | 101 (48.8) | 0.61 |
- Citation: Cruz AJ, Gurram S, Obias I, Luo A, Salmastyan G, Rajagopalan A, Bui S, Sharifi R, Kumar N, Hui C, Cruz Grave E, Yang E, Erondu A, Griggs T. Foregut malignancy after discordant fecal immunochemical test: A cohort study at a United States safety-net hospital. World J Gastrointest Oncol 2026; 18(11): 123432
- URL: https://www.wjgnet.com/1948-5204/full/v18/i11/123432.htm
- DOI: https://dx.doi.org/10.4251/wjgo.123432